

## **AMENDMENTS TO THE CLAIMS**

The present document cancels claims 20-22, 24-50 and 53-92. According to 37 C.F.R. § 1.121(c), after entry of the present amendment, the status of the claims in the case is as follows:

1. (Original) A composition comprising a purified antibody, or antigen-binding fragment or immunoconjugate thereof, wherein said antibody binds to phosphatidylserine and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylserine.
2. (Original) The composition of claim 1, wherein said antibody further binds to phosphatidic acid and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidic acid.
3. (Original) The composition of claim 1, wherein said antibody further binds to phosphatidylinositol and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylinositol.
4. (Original) The composition of claim 1, wherein said antibody further binds to phosphatidylglycerol and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylglycerol.

5. (Original) The composition of claim 1, wherein said antibody further binds to cardiolipin and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to cardiolipin.
6. (Original) The composition of claim 1, wherein said antibody further binds to phosphatidic acid, phosphatidylinositol, phosphatidylglycerol and cardiolipin and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to each of phosphatidic acid, phosphatidylinositol, phosphatidylglycerol and cardiolipin.
7. (Original) The composition of claim 1, wherein said antibody further binds to phosphatidylethanolamine.
8. (Original) The composition of claim 7, wherein said antibody further binds to phosphatidylethanolamine and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylethanolamine.
9. (Original) The composition of claim 1, wherein said antibody has substantially the same phospholipid binding profile as the monoclonal antibody 3G4 (ATCC PTA 4545) as set forth in Table 4.
10. (Original) The composition of claim 1, wherein said antibody has an affinity for phosphatidylserine of at least equal to the affinity of the monoclonal antibody 3G4 (ATCC PTA 4545) for phosphatidylserine as set forth in Table 3.

11. (Original) The composition of claim 1, wherein said antibody has substantially the same phospholipid binding profile as the monoclonal antibody 3G4 (ATCC PTA 4545), as set forth in Table 4, and has an affinity for phosphatidylserine of at least equal to the affinity of the monoclonal antibody 3G4 (ATCC PTA 4545) for phosphatidylserine, as set forth in Table 3.
12. (Original) The composition of claim 1, wherein said antibody is a monoclonal antibody or antigen-binding fragment thereof.
13. (Original) The composition of claim 1, wherein said antibody is an IgG antibody.
14. (Original) The composition of claim 1, wherein said antibody is an antigen-binding fragment of an antibody.
15. (Original) The composition of claim 14, wherein said antibody is an scFv, Fv, Fab', Fab, diabody, linear antibody or F(ab')<sub>2</sub> antigen-binding fragment of an antibody.
16. (Original) The composition of claim 14, wherein said antibody is a CDR, univalent fragment, camelized or single domain antibody.
17. (Original) The composition of claim 1, wherein said antibody is a human, humanized or part-human antibody or an antigen-binding fragment thereof.

18. (Original) The composition of claim 17, wherein said antibody comprises an antigen-binding region of said antibody operatively attached to a human antibody framework or constant region.

19. (Original) The composition of claim 1, wherein said antibody is a chimeric antibody.

**Claims 20-22 canceled**

23. (Original) The composition of claim 1, wherein said antibody is prepared by a process comprising immunizing an animal with activated endothelial cells and selecting from the immunized animal an antibody that binds to phosphatidylserine and effectively competes with the monoclonal antibody 3G4 (ATCC PTA 4545) for binding to phosphatidylserine.

**Claims 24-50 canceled**

51. (Original) The composition of claim 1, wherein said composition is a pharmaceutically acceptable composition that further comprises a pharmaceutically acceptable carrier.

52. (Original) The composition of claim 51, wherein said pharmaceutically acceptable composition is formulated for parenteral administration.

**Claims 53-92 canceled**